Granules added that manufacturing and distribution of its existing products at the facility will continue unaffected.

Granules India's shares fell nearly 8% after the US FDA issued a warning letter regarding its Gagillapur facility, citing ...

"On February 26, 2025, the US FDA issued a Warning Letter to Granules' Gagillapur facility based on its inspection conducted ...

Hyderabad: In a major setback for Hyderabad-based pharma player Granules India Ltd, the US Food and Drug Administration ...

The Warning Letter is dated February 26, 2025 and the facility continues to hold an "Official Action Indicated" (OAI) status.

HYDERABAD: In a major setback to Hyderabad-based pharma player Granules India Ltd, the US Food and Drug Administration (USFDA ...

Granules India's Gagillapur facility receives FDA warning letter, impacting product submissions review until resolved, company remains confident in resolution.

The development may temporarily delay the approval of pending product submissions from the site, but existing manufacturing ...

Telangana: Granules India has announced that the US Food and Drug Administration (US FDA) has issued a Warning Letter to the ...

Drug firm Granules India Ltd on Thursday (February 27) announced that the US FDA has issued a Warning Letter for its ...

Roughly a year after receiving an FDA reprimand at its manufacturing plant in Michigan, Indian drugmaker Piramal Pharma has ...